The designation supports priority engagement with the FDA as Portal Diabetes advances clinical trials and regulatory submissions.

Portal Diabetes has received Breakthrough Device Designation by the Food and Drug Administration (FDA) for its implantable ...

The Enquirer is investigating readers’ medical bills. For our first story, we talked to Ashley Hack, the mom of a 12-year-old with Type 1 diabetes. Do you have a bill you want us to check out? Email ...

Today, Portal Diabetes, Inc. ("Portal") announced its receipt of the Breakthrough Device Designation by the Food and Drug ...

According to the latest Mordor Intelligence report, the insulin delivery devices market size is estimated at USD 33.79 billion in 2026, and is expected to reach USD 49.23 billion by 2031, at a CAGR of ...

WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ -- Even with the advancement of Automated Insulin ...

Feb 18 (Reuters) - Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Medtronic has recalled some of its insulin pumps after injuries and one death were reported due to the device malfunctioning, according to a US Food and Drug Administration announcement on Wednesday.

The US Food and Drug Administration (FDA) has issued a Class I recall for the t:connect mobile app on iOS, which is used to monitor and control the t:slim X2 insulin pump used by people with diabetes.

Its Q4 revenue jumped ~29% YoY on a constant currency basis to $783.8M, exceeding the consensus by $15.1M, as its revenue from its Omnipod insulin pump rose ~28% YoY and ~42% YoY in the U.S. and ...